Related Experiment Video
Updated: Jun 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growth
1Department of Urology, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, PR China.
Abstract:
Most human cancer cells maintain telomere to immortalization through telomerase activity. Inhibition of telomerase activity is a powerful strategy for cancer therapy; however, the potential molecular signals following telomerase suppression are still not clear. Promyelocytic leukemia protein (PML) is an essential component of PML nuclear bodies and a tumor suppressor in bladder cancer. In this study, using mutant human telomerase reverse transcriptase (hTERT) or shRNA to inhibit telomerase activity, we found telomerase suppression increased the expression of PML and resulted in its translocation to the nucleus in bladder cancer T24 cells. Additionally, we found that p53 was recruited into nucleus and colocalized with PML after telomerase suppression. Subsequently, there was a decrease in cell growth in vitro and in vivo and an increase in cell cycle arrest and apoptosis. Furthermore, we showed here that PML is indispensable for p53 nuclear translocation and p21 induction after telomerase inhibition. Therefore, our data indicate that suppression of telomerase could activate the PML-dependent p53 signaling pathway and inhibit bladder cancer cell growth, and also provide new insight into the potential crosstalk between PML and hTERT in bladder cancer cells.
Insights
Inhibiting telomerase in bladder cancer cells boosts promyelocytic leukemia protein (PML) and p53 nuclear activity. This activates a tumor-suppressing pathway, reducing cancer cell growth and promoting apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Human cancer cells often rely on telomerase activity for immortality.
- Inhibiting telomerase is a promising cancer therapy, but downstream molecular effects are unclear.
- Promyelocytic leukemia protein (PML) acts as a tumor suppressor in bladder cancer.
Purpose of the Study:
- To investigate the molecular signals triggered by telomerase suppression in bladder cancer.
- To explore the role of PML and p53 in response to telomerase inhibition.
- To elucidate the mechanism by which telomerase suppression affects bladder cancer cell proliferation.
Main Methods:
- Utilized mutant human telomerase reverse transcriptase (hTERT) and shRNA to inhibit telomerase activity in T24 bladder cancer cells.
- Assessed PML expression and localization using microscopy.
- Analyzed p53 nuclear translocation, cell cycle progression, apoptosis, and cell growth in vitro and in vivo.
Main Results:
- Telomerase suppression led to increased PML expression and nuclear translocation.
- p53 was recruited to the nucleus and colocalized with PML post-telomerase inhibition.
- Inhibition resulted in reduced cell growth, cell cycle arrest, and increased apoptosis.
- PML was found to be essential for p53 nuclear translocation and p21 induction.
Conclusions:
- Telomerase suppression activates a PML-dependent p53 signaling pathway in bladder cancer.
- This pathway effectively inhibits bladder cancer cell growth.
- The study reveals potential crosstalk between PML and hTERT in bladder cancer therapy.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Replicative Cell Senescence
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Negative Regulator Molecules
